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RESEARCH ARTICLE Open Access
Breast cancer distant recurrence lead time
interval by detection method in an
institutional cohort
Henry G. Kaplan1*, Judith A. Malmgren2,3 and Mary K. Atwood1
Abstract
Background: Lead time, the interval between screen detection and when a disease would have become clinically
evident, has been cited to explain longer survival times in mammography detected breast cancer cases (BC).
Methods: An institutional retrospective cohort study of BC outcomes related to detection method (mammography
(MamD) vs. patient (PtD)). Cases were first primary invasive stage I-III BC, age 40–74 years (n = 6603), 1999–2016.
Survival time was divided into 1) distant disease-free interval (DDFI) and 2) distant disease-specific survival (DDSS) as
two separate time interval outcomes. We measured statistical association between detection method and
diagnostic, treatment and outcome variables using bivariate comparisons, Cox proportional hazards analyses and
mean comparisons. Outcomes were distant recurrence (n = 422), DDFI and DDSS.
Results: 39% of cases were PtD (n = 2566) and 61% were MamD (n = 4037). MamD cases had a higher percentage
of Stage I tumors [MamD 69% stage I vs. PtD 31%, p < .001]. Rate of distant recurrence was 11% among PtD BC
cases (n = 289) vs. 3% of MamD (n = 133) (p < .001). Order of factor entry into the distant recurrence time interval
(DDFI) model was 1) TNM stage (p < .001), 2) HR/HER2 status (p < .001), 3) histologic grade (p = .005) and 4)
detection method (p < .001). Unadjusted PtD DDFI mean time was 4.34 years and MamD 5.52 years (p < .001),
however when stratified by stage, the most significant factor relative to distant recurrence, there was no significant
difference between PtD and MamD BC. Distant disease specific survival time did not differ by detection method.
Conclusion: We observed breast cancer distant disease-free interval to be primarily associated with stage at
diagnosis and tumor characteristics with less contribution of detection method to the full model. Patient and
mammography detected breast cancer mean lead time to distant recurrence differed significantly by detection
method for all stages but not significantly within stage with no difference in time from distant recurrence to death.
Lead time difference related to detection method appears to be present but may be less influential than other
factors in distant disease-free and disease specific survival.
Keywords: Lead time, Lead time bias, Survival, Breast cancer, Detection, Cox proportional hazards model,
Mammography, Early diagnosis
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Background
The incidence of recurrent metastatic breast cancer
(rMBC) and breast cancer mortality have decreased in re-
cent years coincident with improvement in breast cancer
survival due to both reduced incidence of higher stage dis-
ease related to mammography screening and improved
adjuvant systemic therapy for invasive stage I-III disease
[1–4]. Debate and analysis continue about the relative
contribution of early detection of breast cancer by mam-
mography screening to improved survival [5–8]. From na-
tional mammography screening program surveillance
reports, mammography detected tumors are more often
smaller and lower stage with better survival [9].
Mammography screening has shifted breast cancer de-
tected to more early stage (stage 0 (DCIS) and stage I-II)
and less late stage breast cancer (stage III and IV) over
time in screened populations [10–16]. The mechanism
behind early detection is the use of mammography im-
aging to screen asymptomatic women at regular intervals
for preclinical disease recognized by screening examin-
ation and advancing time of diagnosis by the interval
that would otherwise occur for breast cancer detection
without screening [17, 18].
Lead time is described as the interval between screen-
ing detection and when the disease would have become
clinically evident without screening. Lead time gained
from screening detection may lengthen the interval
when added to the time over which evident disease pro-
gresses. Lead time is not a measure used to evaluate
breast cancer survival improvement associated with
screening mammography which is measured by differen-
tial breast cancer mortality over time between screened
and unscreened populations.
We are now in a time of accepted validity for mammog-
raphy screening with evidence-based guidelines adopted
and promoted in the United States and Europe [19–21].
Mammography screening is not institutionalized in the
United States where it is an opportunistic choice based on
health care access, screening guideline knowledge, insur-
ance coverage and care giver recommendation [22].
Timing and incidence of invasive breast cancer distant
disease recurrence provides an opportunity to measure
lead time by comparing time to distant recurrence after
initial diagnosis and post recurrence survival as a func-
tion of detection method. In our retrospective institu-
tional cohort study, the objective was to measure time to
distant disease recurrence and time from distant recur-
rence to death among invasive breast cancer patients to
assess whether lead time is differential by how the breast
cancer was detected.
Methods
To assess the contribution of lead time to survival
among mammography detected BC cases we conducted
lead time analysis comparing mammography (MamD) to
patient detected (PtD) BC using time to distant recur-
rence as the first interval (DDFI) and time from distant
recurrence to last follow up or death from disease as the
second interval (distant disease specific survival (DDSS))
separately and combined. We compared distant recur-
rence lead time by detection method to DDFI and
DDSS, the two component time intervals of disease spe-
cific survival, and modeled the relative contribution of
detection method to DDFI. We also assessed relative
rMBC incidence by detection method.
Study design
We conducted a retrospective cohort analysis of all first
primary stage I-III invasive BC cases age 40–74 from
1990 to 2016, with follow-up through 2018 for distant
recurrence and vital status (n = 6603). Age 40–74 years
was selected based on screening recommendations
during this time period [19, 23, 24]. Non-surgical cases
(n = 18), patients who refused recommended treatment
other than surgery (n = 24), cases with unknown method
of detection (n = 11) and cases with unknown cancer
status at follow up (n = 139) were excluded from the
analysis. Inflammatory breast cancer (IBC) (T4) cases
were excluded (n = 125), as 96% of the IBC cases were
patient detected and symptom based not detected by
mammography. Patient (PtD) and mammography de-
tected (MamD) BC was included and BC found by a
medical professional from a lump or abnormality during
routine physical examination was excluded (n = 295)
(Fig. 1).
Our institutional breast cancer registry database
contains detailed information on diagnosis, pathology,
staging, treatment, tumor markers, and vital status at
follow up including cause-specific death. Incident BC
cases are entered at time of diagnosis into the HIPAA
compliant and IRB approved registry. Patient vital and
disease status including date, site and type of recurrence
and date and cause of death are collected prospectively
through annual updates by a certified cancer registrar
complete through 2018 for this cohort. Follow-up status
was obtained from 1) electronic chart review, 2) IRB-
approved physician directed follow-up letter, 3) the
institution’s cancer registry, and 4) Surveillance Epidemi-
ology and End Results (SEER) Seattle-Puget Sound
Registry [25].
Distant disease recurrence (rMBC) was restricted to
first presentation of distant disease excluding dates of
subsequent disease progression. Hormone receptor posi-
tivity was estrogen and/or progesterone receptor positive
(HR positive) and HR negative if negative for both. Self-
reported race was coded white/non-white. All cases were
coded to AJCC 7 classic anatomic staging across all
years [26]. TNM stage 0 were excluded from the analysis
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as few were patient detected and distant recurrence was
a rare event. Distant recurrence (rMBC) was designated
if distant disease diagnosis occurred 3 months or more
post initial diagnosis.
Breast cancer detection method was obtained by
medical record review by a certified cancer registrar.
Mammography detected was assigned to breast cancer
discovered by routine mammography in the absence
of complaints or known physical findings or as a re-
peat or diagnostic mammogram to verify a previous
equivocal mammography finding. Patient detection
was assigned if the patient presented with personally
detected breast symptoms, such as a palpable lump,
pain, swelling, nipple discharge, or bleeding which
prompted a doctor visit. Patients with self-detected
tumors may have subsequently had a mammogram or
ultrasound done but would still be categorized as a
patient-detected breast cancer from first presentation.
Detection method was recorded by the physician at
time of diagnosis and was only assigned if it was cer-
tain from the record.
Pearson chi-square test comparisons of categorical
characteristics by detection method and mean compari-
sons for continuous variables were used (F statistic). Dis-
tant disease-free interval (DDFI) was time from primary
BC diagnosis to distant recurrence, distant disease spe-
cific survival (DDSS) was time from distant recurrence
(rMBC) to last follow-up or death from this disease,
and disease specific survival (DSS) was total time
from initial BC diagnosis to last follow-up or death
from this disease. By dividing DSS into two compo-
nent parts, time to distant disease recurrence (DDFI)
and time from distant disease recurrence to last fol-
low up or death from disease (DDSS), we are able to
identify which portion of survival time is affected by
lead time and evaluate accordingly. Kaplan-Meier esti-
mation was used to calculate 5-year DDFI, DDSS and
DSS rates (log rank tests).
Covariates significant by detection method were used
to build the model, informed by the chi-square analysis
and tested a priori using stepwise entry. The multivari-
able Cox proportional hazards model was used to esti-
mate adjusted hazard ratios (HzR) and corresponding
95% confidence intervals (CI) using DDFI as the out-
come. We evaluated the proportional hazards assump-
tion by plotting ln{−ln(survival)} curves for the ordinal
covariate of diagnosis year versus ln (at risk time) and
on the basis of Schoenfeld residuals after fitting individ-
ual Cox models. We found no evidence suggesting sub-
stantial violation of the proportionality assumption
graphically or in tests for interaction with the logarithm
of survival time [27]. Effect modification was evident
from the Cox proportional hazards analysis with stage
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analysis was stratified by stage to compare detection
method differences in survival [28, 29]. All p-values
were 2-sided and analyses were conducted using SPSS
v.26 [30].
Results
Between 1999 and 2016, 39% of invasive stage I-III
breast cancer cases were patient detected (n = 2566) and
61% were mammography detected (n = 4037). Sixty nine
percent of MamD BC cases were stage I at diagnosis,
27% stage II and 4% stage III. Thirty one percent of PtD
BC were stage I at diagnosis, 51% stage II and 18% stage
III (p < .001). PtD BC patients trended to younger age at
diagnosis, 37% age 40–49 years vs. 19% MamD and
MamD cases trended older [mean age PtD = 55 years vs
MamD = 58 years (p < .001)]. More MamD BC cases
identified as white race (84% vs 77%) Table 1.
Tumor characteristics differed with MamD BC cases
more likely HR+/HER2- [64% vs. 36% PtD BC] and the
reverse for triple negative breast cancer (TNBC) [39%
MamD BC vs 61% PtD BC) (p < .001)]. MamD tumors
were smaller and more often <= 2 cm in size (77%) vs.
42% of PtD BC cases (p < .001) [mean tumor size:
MamD = 1.51 cm, PtD = 2.91 cm (p < .001)]. Twenty one
percent of MamD BC had positive lymph nodes vs
44% of PtD BC patients (p < .001). Histologic type
was not significantly different. PtD BC nuclear grade
was more often high grade than MamD BC (52% vs.
32%). PtD and MamD cases were both majority high
grade, PtD 76% and MamD 62% (p < .001). 15% or
fewer of each group had surgery treatment only, with
the majority of MamD BC cases receiving surgery/ra-
diation treatment (50%) and the majority of PtD BC
cases receiving surgery/radiation/chemotherapy treat-
ment (54%) (p < .001) Table 1.
Average follow up was 9 years [range 1.7 to 20.4 years].
Eleven percent of PtD BC cases had a distant recurrence
(rMBC) (n = 289) compared to 3% of MamD BC (n =
133). Five-year disease specific survival was 99% for
MamD BC and 95% for PtD BC (p < .001). Five-year
overall survival was 97% for MamD BC and 93% for PtD
BC (p < .001) Fig. 2.
Using all cases in the analytic set (n = 6333) the
distant disease-free interval five-year survival rate was
98% for MamD BC and 92% for PtD BC (p < .001)
Fig. 3. For the subset of patients with distant recur-
rence (rMBC = 422), distant disease-free interval five-
year survival was 43% for MamD BC and 30% for
PtD BC (p < .001) [DDFI: time from initial diagnosis
to last follow-up or distant disease]. Distant disease
specific five-year survival was 11% for rMBC MamD
BC and 10% for rMBC PtD BC (not significant) (n =
422) [DDSS: time from distant recurrence to death
from disease or last follow-up] Fig. 4.
In the forward conditional Cox proportional hazards
model of time to distant recurrence (DDFI) using rMBC
as the outcome (n = 6603), variable order of entry into
the model at <.05 significance level was 1) TNM stage 2)
HR/HER2 status, 3) histologic grade, and 4) detection
method. The majority chi-square change in the model
by order of entry was attributable to TNM stage I-III at
diagnosis (Wald chi-square change = 353.10) and least of
all to detection method (Wald chi-square change = 8.67)
although detection method was significant and retained
in the model in last position. The model was adjusted
for age, race, and diagnosis year which were not signifi-
cant Table 2.
Mean unadjusted time to distant recurrence (DDFI)
was significantly different [MamD 5.52 years, PtD 4.34
years (p = .001) (difference 1.18 years)] Fig. 5. Unadjusted
for detection method mean DDFI interval was signifi-
cantly different between stages [I = 5.74 years, II = 5.00
years, III = 3.83 years, p < .001]. Mean times to distant
disease recurrence for PtD and MamD BC stratified by
stage to adjust for effect modification differed but were
not statistically significantly different [stage I: MamD
6.02 years, PtD 5.35 years (difference 8 months), p = .902;
stage II: MamD 5.66 years, PtD 4.69 years (difference 12
months), p = .537; Stage III: MamD 4.49 years, PtD 3.67
years (difference 10months, p = .597]. Mean time from
distant disease recurrence to death or last follow up
(DDSS) did not differ by detection method overall
[MamD 2.27 years, PtD 2.38 years (p = .154)] Fig. 5.
Discussion
The majority of distant disease recurrence (68%) oc-
curred among patient-detected cases with an incidence
rate of 11% compared to 3% distant recurrence among
mammography detected breast cancer cases. Mean time
to distant recurrence was shorter by 8–12months for
patient-detected BC than it was for mammography-
detected BC but did not differ significantly when strati-
fied by the effect modifier stage at diagnosis. Stage at
diagnosis was more strongly associated with the out-
come distant recurrence than other factors in the model
including detection method. There was no difference in
time from distant disease recurrence to last follow-up or
death from disease by detection method. Breaking down
lead time interval by mammography/patient detection
and stage revealed that differential lead time was only
present in the initial interval from diagnosis to distant
recurrence.
Time from initial diagnosis to distant recurrence is the
first interval and time from distant recurrence to last
follow-up or death is the second interval in disease pro-
gression and disease specific survival. Time to disease
progression would be equivalent between screening and
symptomatic presentation if lead time differences were
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Table 1 Descriptive characteristics by detection method 1999–2016 (n = 6603)
PtD MamD p
value(n = 2566) (n = 4037)
Stage N (column %) N (column %)
I 792 (31%) 2772 (69%) <.001
II 1314 (51%) 1108 (27%)
III 460 (18%) 157 (4%)
Age
40–49 950 (55%) 765 (45%) <.001
50–64 1216 (36%) 2189 (64%)
65–74 400 (27%) 1083 (73%)
Mean age (range, F statistic) 54 (40–74) 58 (40–74) <.001
Race
White 1986 (37%) 3388 (63%) <.001
Non-White 580 (47%) 649 (53%)
Hormone receptor status
HR+ 2081 (36%) 3641 (64%) <.001
HER2 status
Her2+ (HR- or HR+) 458 (46%) 534 (54%) <.001
HR/HER2 status at initial diagnosis
HR+/HER2- 1718 (36%) 3110 (64%) <.001
HR+/HER2+ 332 (45%) 399 (55%)
HR−/HER2- 340 (61%) 216 (39%)
HR−/HER2+ 126 (49%) 134 (51%)
Histologic type initial primary breast tumor
Ductal 2122 (39%) 3312 (61%) .287
Lobular 258 (39%) 411 (61%)
Lobular/Ductal mixed 120 (40%) 177 (60%)
Other cancer 64 (33%) 133 (67%)
Nuclear grade initial primary breast tumor
Low/Intermediate 1189 (31%) 2675 (69%) <.001
High 1340 (51%) 1289 (49%)
Histologic grade initial primary breast tumor
Low/Intermediate 583 (29%) 1447 (71%) <.001
High 1943 (44%) 2498 (56%)
Tumor size (mean, range, F statistic) 2.91 (.10, 18.00) 1.51 (.05, 17.00) <.001
# Positive nodes (mean, range, F statistic) 1.67 (0–44) .57 (0–35) <.001
Treatment
Surgery only 339 (36%) 614 (64%) <.001
Surgery/radiation 575 (22%) 1997 (78%)
Surgery/chemotherapy 412 (53%) 372 (47%)
Surgery/radiation/chemotherapy 1240 (54%) 1054 (46%)
Distant recurrence
Yes 289 (68%) 133 (32%) <.001
Kaplan et al. BMC Cancer         (2020) 20:1124 Page 5 of 11
not present. Although there were differences in DDFI
mean time comparisons by stage, the differences were
not significant. In the model adjusted for stage, HR/
HER2 status and histologic grade, detection method
ranked last in the model with a small but significant ef-
fect as measured by the Wald chi-square statistic. Lead
time interval related to detection method appears to be
a less influential factor in distant disease-free interval as
other factors related to early diagnosis, stage, HR/HER2
status and histologic grade, represent the majority of ef-
fect on distant disease-free interval superseding the ef-
fect of detection method.
The survival curves illustrate differential survival by
detection method with better mammography detected
breast cancer survival. The survival curves of the rMBC
patient group illustrate the differential survival which oc-
curs prior to metastatic recurrence with no difference in
time from distant disease to death as a function of detec-
tion method.
As a result of stage shift over time related to mam-
mography screening, stage at diagnosis, histologic grade,
and hormone receptor/HER2 status are not evenly dis-
tributed between patient and mammography detected
invasive breast cancer cases. Stage at diagnosis is most
strongly associated with the outcome, distant disease re-
currence, in the Cox proportional hazards model The
magnitude of the effect of detection method, on the out-
come, length of time to distant recurrence, differs sub-
stantially by stage at diagnosis. Stratified analysis adjusts
for effect modification and provides an opportunity to
measure differential lead time by detection method. The
natural ordering of stage at diagnosis lends itself to a lin-
ear approach for stratified analysis. From our analysis it
appears the difference in survival is associated with the
Fig. 2 DSS and OS by detection method
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lengthened first interval, time to distant recurrence and
not the second interval, time from distant recurrence to
death.
Strengths and limitations
Mammography screening in the United States relies on
opportunistic mammography screening based on United
States Preventive Services Task Force, the American
Cancer Society and other organizations recommenda-
tions unlike countries with organized screening pro-
grams [23, 24, 31, 32]. Screening is therefore predicated
on self-initiation of screening mammography or
prompted by a care provider or health care system. In
the absence of a national screening program and as
screening participation data connected to outcomes is
not readily available, we tested the differential lead time
hypothesis using an institutional cohort and mammog-
raphy detected breast cancer as a proxy for screen detec-
tion compared to patient detected breast cancer in a
real-world setting. Inflammatory breast cancer and phys-
ician detected breast cancer, both rare events (< 5%),
were not included in the analysis as differential presenta-
tion and survival did not contribute to specific hypoth-
esis testing of exposure (mammography detected
compared to patient detected BC survival time) and
could affect the generalizability of outcomes by diluting
the measured effect.
Mammography screening participation rate reported
in the year prior to 2012 was 57% in Washington State,
very close to our observed rate of 61% mammography
detection [33]. We do not have information regarding
age appropriate mammography screening program par-
ticipation or time interval between last non-diagnostic
mammogram and breast cancer discovered by
mammography. While it has been speculated that some
mammography screen detected cancer would not be-
come clinically evident in a woman’s life time, to date
there are no published reports of screen detected breast
cancer regression or spontaneous disappearance [34].
Only invasive breast cancer stage I-III were included in
the analysis as stage 0 may be interpreted as an overdi-
agnosis category detected by mammography and there-
fore not compatible with survival comparison by
detection method [8].
Interpretation: comparison to other studies
In a study of 233 patients diagnosed in 1988 patients
with mammography screen-detected breast cancer had
superior prognosis primarily due to the mammography
detected better prognosis characteristics and low stage
breast cancer at diagnosis compared to the non-
mammography screen detected group [35]. Within
stage the mammography detected invasive breast can-
cers had superior prognosis. The minimal lead time
estimate from early screening studies conducted by
the Health Insurance Plan of Greater New York was
10 months with estimates from statistical models ran-
ging from 7 to 13 months [17, 18]. Their statistical
models suggested the average lead time gained by
screening to be about a year. In a more recent study
by Allgood et al., it was found the majority of survival
advantage of screen detection was due to size and
node status [36].
Corrections for and explanation of lead time, or lead
time bias as it is called in relation to mammography
screening, largely rely on modelling and/or statistical es-
timates applied to population data and lack information
on time to distant recurrence and time to death from
Fig. 3 DDFI survival: all cases (n = 6603)
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distant disease [37–39]. In our institutional cohort with
distant recurrence date and distant disease survival time
we have a different approach to evaluate lead time using
real as opposed to modelled data.
Lead time interval is the time between screening de-
tection and when disease would become clinically evi-
dent without screening, assuming the same disease
progression post diagnosis regardless of detection
method. In the case of invasive breast cancer, it appears
lead time advance by mammography detection adds to
evident disease progression time extending the time
interval to distant recurrence regardless of stage at diag-
nosis. This may be due to as yet unidentified benefit re-
lated to mammography screening [16, 40]. We observed
no difference in distant disease survival by detection
method indicating lead time only factors in the first
time-interval of disease progression and once distant
metastatic disease is present disease progression is the
same.
Generalizability
The Seattle-Puget Sound region where the study was
conducted has high socioeconomic status (SES) with
ready access to care and high insured percentage [41].
Patients treated at this institution may not be compar-
able to other U. S. geographic areas. Our breast cancer
survival rates have been documented by national com-
parisons to have greater improvement over time than
national rates [42].
Fig. 4 DDFI survival and DDSS by Detection Method: rMBC only (n = 422)
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Conclusions
From our analysis, mammography detected breast can-
cer was associated with earlier stage, higher percentage
HR positive/HER2 negative subtype and lower histologic
grade disease, factors associated with reduced distant re-
currence and better outcomes. Earlier stage at diagnosis
was the dominant factor affecting better survival, giving
mammography detected breast cancer cases an overall
survival advantage. However, once distant disease oc-
curred, no distant disease survival time difference was
observed in spite of more unfavorable PtD breast cancer
initial phenotypes. Time to distant recurrence did not
differ significantly by detection method stratified by
stage and had marginal significance in distant disease
modelling. The combined modelling analysis and com-
parison of lead times indicates lead time presence but
less significance compared to other diagnostic character-
istics related to survival.
Lead time interval related to detection method may
have been a factor with more significant effect in de-
cades preceding current diagnostic and tumor specific
treatment options as over time there has been a shift to
earlier stage at diagnosis and declining distant recur-
rence rates. Without comparative studies of time from
diagnosis to distant recurrence and distant recurrence to
death from earlier decades, we do not know prior mag-
nitude of effect. Further, lead time interval cannot be
measured directly for an entire population, in which the
Fig. 5 rMBC disease survival time by detection method and DDFI+DDSS stratified by stage and detection method (n = 422)
Table 2 Cox proportional hazards model of distant disease-free interval: outcome = rMBCa (n = 6603)
By order of entry into the model: HzR (95% CI) p value Wald chi-square Model Chi-square change df
TNM Stage I reference <.001 200.86 353.10 2
TNM Stage II 3.30 (2.47, 4.42) 64.96
TNM Stage III 9.19 (6.70, 12.60) 190.03
HR/HER2 status: initial diagnosis
HR+/HER2- reference <.001 48.50 55.00 2
HR+ or HR−/HER2+ .86 (.66, 1.13) 1.13
HR−/HER2- 2.22 (1.73, 2.84) 40.31
Histological grade primary tumor
Low/Intermediate reference <.001 7.89 29.04 1
High 1.49 (1.13, 1.98)
Detection method
MamD reference <.001 25.84 8.51 1
PtD 1.80 (1.43, 2.25)
aadjusted for age, race and diagnosis year (not significant in the model)
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vast majority of patients never suffer a distant recur-
rence. However, in the modern era of diagnosis and
treatment it appears lead time interval related to method
of detection while present is not a dominant factor af-
fecting survival relative to other breast cancer character-
istics. Early diagnosis, measured by earlier stage breast
cancer at diagnosis irrespective of how the breast cancer
was detected, is most directly associated with better out-
comes and survival. Importantly it appears lead time is a
phenomenon related to earlier stage diagnosis by mam-
mography detection. The aim of screening is to find dis-
ease at an earlier more treatable stage which screening
mammography appears to accomplish.
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